| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers S > Headlines for St. Jude Medical Inc. > News item |
St. Jude Medical launches new vascular closure device
By Lisa Kerner
Erie, Pa., March 17 - St. Jude Medical, Inc. said it has launched its Food and Drug Administration-approved vascular closure device, the Angio-Seal VIP.
The device is approved for both diagnostic and interventional procedures, giving physicians an improved method for sealing arterial catheterization access sites, according to a company news release.
Angio-Seal VIP provides extra coverage on the artery surface to more effectively stop bleeding and its coated suture makes sealing and re-entering access sites easier.
All components of the Angio-Seal VIP are fully absorbed into the body within 60 to 90 days.
"In our experience with Angio-Seal VIP, which includes use in more than 550 patients, we believe that the improvements have been noticeable, particularly in interventional procedures," Jack Martin, chief of cardiology at Main Line Health in Bryn Mawr, Pa., said in the release.
"Also, we believe that earlier patient ambulation and earlier discharge helps patients get back to their lives sooner, as well as reducing time and cost in the recovery room."
Nearly 10 million catheterizations, in which a thin tube is inserted into the femoral (leg) artery, are performed worldwide annually, according to St. Jude Medical.
The use of vascular closure devices reduces the time patients spend in the catheterization lab and recovery area and also shortens hospital stays, according to the release.
Patients with Angio-Seal devices are able to more quickly resume normal activity, walking within 20 minutes and leaving the hospital one hour after treatment.
St. Jude Medical provides medical device technology and services in five focus areas: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. The company is based in St. Paul, Minn.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.